A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191-Reference-Cited by-同舟云学术

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

Published:2015-10-15 Issue:6 Volume:57 Page:1463-1466
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Hay Annette E.,Murugesan Alli,DiPasquale Ashley M.,Kouroukis Tom,Sandhu Irwindeep,Kukreti Vishal,Bahlis Nizar J.,Lategan Johan,Reece Donna E.,Lyons John F.,Sederias Joana,Xu Hao,Powers Jean,Seymour Lesley K.,Reiman Tony

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1091927

Reference14 articles.

1. The cellular geography of Aurora kinases

2. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition

3. Molecular heterogeneity and centrosome-associated genes in multiple myeloma

4. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells

5. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Aurora kinase inhibitor AT9283 inhibits Burkitt lymphoma growth by regulating Warburg effect;PeerJ;2023-12-11

2. Aurora B Inhibitors as Cancer Therapeutics;Molecules;2023-04-11

3. AT9283, 1-Cyclopropyl-3-(3-(5-(Morpholinomethyl)-1H-Benzo[d]Imidazole-2-yl)-1H-Pyrazol-4-yl) Urea, Inhibits Syk to Suppress Mast Cell-Mediated Allergic Response;Biomolecules & Therapeutics;2022-11-01

4. Posttranslational modification of Aurora A‐NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma;Clinical and Translational Medicine;2022-04

5. Aurora B kinase: a potential drug target for cancer therapy;Journal of Cancer Research and Clinical Oncology;2021-05-28